272 related articles for article (PubMed ID: 30262398)
1. Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.
Casey RT; Giger O; Seetho I; Marker A; Pitfield D; Boyle LH; Gurnell M; Shaw A; Tischkowitz M; Maher ER; Chatterjee VK; Janowitz T; Mells G; Corrie P; Challis BG
Semin Oncol; 2018 Jun; 45(3):151-155. PubMed ID: 30262398
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
[TBL] [Abstract][Full Text] [Related]
3. PD-1 Blockade in Advanced Adrenocortical Carcinoma.
Raj N; Zheng Y; Kelly V; Katz SS; Chou J; Do RKG; Capanu M; Zamarin D; Saltz LB; Ariyan CE; Untch BR; O'Reilly EM; Gopalan A; Berger MF; Olino K; Segal NH; Reidy-Lagunes DL
J Clin Oncol; 2020 Jan; 38(1):71-80. PubMed ID: 31644329
[TBL] [Abstract][Full Text] [Related]
4. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab.
Caccese M; Barbot M; Ceccato F; Padovan M; Gardiman MP; Fassan M; Denaro L; Emanuelli E; D'Avella D; Scaroni C; Zagonel V; Lombardi G
Anticancer Drugs; 2020 Feb; 31(2):199-204. PubMed ID: 31702999
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports.
Mota JM; Sousa LG; Braghiroli MI; Siqueira LT; Neto JEB; Chapchap P; Hoff AAO; Hoff PM
Medicine (Baltimore); 2018 Dec; 97(52):e13517. PubMed ID: 30593126
[TBL] [Abstract][Full Text] [Related]
6. Integrative computational immunogenomic profiling of cortisol-secreting adrenocortical carcinoma.
Baechle JJ; Hanna DN; Sekhar KR; Rathmell JC; Rathmell WK; Baregamian N
J Cell Mol Med; 2021 Nov; 25(21):10061-10072. PubMed ID: 34664400
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
8. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
Lang J; Capasso A; Jordan KR; French JD; Kar A; Bagby SM; Barbee J; Yacob BW; Head LS; Tompkins KD; Freed BM; Somerset H; Clark TJ; Pitts TM; Messersmith WA; Eckhardt SG; Wierman ME; Leong S; Kiseljak-Vassiliades K
J Clin Endocrinol Metab; 2020 Jan; 105(1):26-42. PubMed ID: 31513709
[TBL] [Abstract][Full Text] [Related]
9. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
10. Mismatch Repair Protein Deficiency/Microsatellite Instability Is Rare in Cholangiocarcinomas and Associated With Distinctive Morphologies.
Ju JY; Dibbern ME; Mahadevan MS; Fan J; Kunk PR; Stelow EB
Am J Clin Pathol; 2020 Apr; 153(5):598-604. PubMed ID: 31844887
[TBL] [Abstract][Full Text] [Related]
11. Familial Adrenocortical Carcinoma in Association With Lynch Syndrome.
Challis BG; Kandasamy N; Powlson AS; Koulouri O; Annamalai AK; Happerfield L; Marker AJ; Arends MJ; Nik-Zainal S; Gurnell M
J Clin Endocrinol Metab; 2016 Jun; 101(6):2269-72. PubMed ID: 27144940
[TBL] [Abstract][Full Text] [Related]
12. The role of immune checkpoint inhibitor therapy in advanced adrenocortical carcinoma revisited: review of literature.
Brabo EP; Moraes AB; Neto LV
J Endocrinol Invest; 2020 Nov; 43(11):1531-1542. PubMed ID: 32468513
[TBL] [Abstract][Full Text] [Related]
13. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
[TBL] [Abstract][Full Text] [Related]
14. New perspectives for mitotane treatment of adrenocortical carcinoma.
Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
16. An Interesting Case of Hepatic Adrenocortical Carcinoma.
Permana H; Darmawan G; Ritonga E; Kusumawati M; Miftahurachman M; Soetedjo NN
Acta Med Indones; 2018 Jul; 50(3):257-259. PubMed ID: 30333277
[TBL] [Abstract][Full Text] [Related]
17. Advanced Adrenocortical Carcinoma: Current Perspectives on Medical Treatment.
Araújo AN; Bugalho MJ
Horm Metab Res; 2021 May; 53(5):285-292. PubMed ID: 33962475
[TBL] [Abstract][Full Text] [Related]
18. Lynch Syndrome in Thai Endometrial Cancer Patients.
Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
[TBL] [Abstract][Full Text] [Related]
20. The computed tomography adrenal wash-out analysis properly classifies cortisol secreting adrenocortical adenomas.
Humbert AL; Lecoanet G; Moog S; Bouderraoui F; Bresler L; Vignaud JM; Chevalier E; Brunaud L; Klein M; Cuny T
Endocrine; 2018 Mar; 59(3):529-537. PubMed ID: 29332161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
